All In Biotech

Drug Trial Radar · NCT01815736

Study to Evaluate Switching From a TDF-Containing Combination Regimen to a TAF-Containing Fixed Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Positive Participants

A Phase 3, Open-Label Study to Evaluate Switching From a TDF-Containing Combination Regimen to a TAF-Containing Combination Single Tablet Regimen (STR) in Virologically-Suppressed, HIV-1 Positive Subjects

Last checked: Nov 19, 2026Latest source record: Apr 13, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,443 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,443

Actual

Start

Mar 27, 2013

Primary completion

Mar 16, 2015

Study completion Apr 1, 2020

Sponsor

Lead sponsor
Gilead SciencesGilead Sciences (GILD)
Sponsor type
Industry
First posted
Mar 21, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study is to evaluate the non-inferiority of switching to a tenofovir alafenamide (TAF)-containing fixed dose combination (FDC) relative to maintaining tenofovir disoproxil fumarate (TDF)-containing combination regimens in virologically suppressed HIV-infected participants as determined by having HIV-1 RNA \< 50 copies/mL at Week 48.

Conditions

  • HIV
  • HIV Infections

Interventions

  • E/C/F/TAFDrug

    150/150/200/10 mg FDC tablet administered orally once daily

  • E/C/F/TDFDrug

    150/150/200/300 mg FDC tablet administered orally once daily

  • EFV/FTC/TDFDrug

    600/200/300 mg FDC tablet administered orally once daily

  • RTVDrug

    100 mg tablet administered orally once daily

  • ATVDrug

    300 mg capsule administered orally once daily

  • FTC/TDFDrug

    200/300 mg tablet administered orally once daily

  • COBIDrug

    150 mg tablet administered orally once daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48Time frame: Week 48

Locations

167 sites in 20 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama

  • Southwest Center for HIV/AIDS

    Phoenix, Arizona

  • Spectrum Medical Group

    Phoenix, Arizona

  • Health for Life Clinic PLLC

    Little Rock, Arkansas

  • AHF Research Center

    Beverly Hills, California

  • Michael Keith Wensley, MD, Inc., A Medical Corporation

    Costa Mesa, California

  • Living Hope Clinical Foundation

    Long Beach, California

  • Kaiser Permanente

    Los Angeles, California

  • Jeffrey Goodman Special Care Clinic

    Los Angeles, California

  • Peter J Ruane, MD, Inc

    Los Angeles, California

  • Anthony Mills MD Inc

    Los Angeles, California

  • Orange Coast Medical Group

    Newport Beach, California

  • Alameda County Medical Center

    Oakland, California

  • East Bay AIDS Center

    Oakland, California

  • Stanford University

    Palo Alto, California

  • University of California, Davis Medical Center

    Sacramento, California

  • Kaiser Permanente Medical Group

    Sacramento, California

  • La Playa Medical Group and Clinical Research

    San Diego, California

  • Metropolis Medical Group

    San Francisco, California

  • Kaiser Permanente Medical Center, Clinical Trials Unit

    San Francisco, California

  • Kaiser Permanente Hospital

    San Leandro, California

  • Apex Research LLC

    Denver, Colorado

  • Greenwich Hospital

    Greenwich, Connecticut

  • Yale University HIV Clinical Trials Program

    New Haven, Connecticut

  • Dupont Circle Physicians Group

    Washington D.C., District of Columbia

  • Whitman Walker Clinic

    Washington D.C., District of Columbia

  • Capital Medical Associates, PC

    Washington D.C., District of Columbia

  • George Washington University Medical Faculty Associates

    Washington D.C., District of Columbia

  • Therafirst Medical Center

    Fort Lauderdale, Florida

  • Broward Health/Comprehensive Care Center

    Fort Lauderdale, Florida

  • Gary J. Richmond,M.D.,P.A.

    Fort Lauderdale, Florida

  • Midway Immunology and Research Center

    Ft. Pierce, Florida

  • The Kinder Medical Group

    Miami, Florida

  • Wohlfeiler, Piperato and Associates, LLC

    Miami Beach, Florida

  • Orlando Immunology Center

    Orlando, Florida

  • IDOCF/ Value Health MD, LLC

    Orlando, Florida

  • University of South Florida HIV Clinical Research Unit / Hillsborough County Health Department

    Tampa, Florida

  • Infectious Disease Research Institute Inc.

    Tampa, Florida

  • St. Joseph's Comprehensive Research Institute

    Tampa, Florida

  • AIDS Research Consortium of Atlanta

    Atlanta, Georgia

Showing 40 of 167 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.